ACAD4:05 PMAcadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidanceacadia.com
ACAD4:05 PMAcadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Careeracadia.com
ACAD9:05 AMAcadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meetingacadia.com
ACAD4:05 PMAcadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026acadia.com
ACAD9:05 AMAcadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndromeacadia.com
ACAD4:05 PMAcadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndromeacadia.com